Cancer immunotherapy - revisited

被引：323

作者：

Lesterhuis, W. Joost ^{[1
]}

Haanen, John B. A. G. ^{[2
,3
]}

Punt, Cornelis J. A. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

[2] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Med Oncol, NL-1066 CX Amsterdam, Netherlands

[3] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands

来源：

NATURE REVIEWS DRUG DISCOVERY | 2011年 / 10卷 / 08期

关键词：

REGULATORY T-CELLS; BACILLUS-CALMETTE-GUERIN; ACTIVATED KILLER-CELLS; METASTATIC MELANOMA; DENDRITIC CELLS; RECOMBINANT INTERLEUKIN-2; ADOPTIVE IMMUNOTHERAPY; SELECTIVE DEPLETION; CLINICAL-RESPONSES; ANTITUMOR-ACTIVITY;

D O I：

10.1038/nrd3500

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Our insight into antitumour immune responses has increased considerably during the past decades, yet the development of immunotherapy as a treatment modality for cancer has been hampered by several factors. These include difficulties in the selection of the optimal dose and schedule, the methods of evaluation, and financial support. Although durable clinical remissions have been observed with various immunotherapeutic strategies, the percentage of patients who benefited from these interventions has remained too small to justify the general use of such strategies. However, the recent positive results of clinical trials with novel immunoactive drugs as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy may herald a new era for the immunotherapy of cancer.

引用

页码：591 / 600

页数：10

共 115 条

[1] Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes [J].

Alfaro, C. ;

Suarez, N. ;

Gonzalez, A. ;

Solano, S. ;

Erro, L. ;

Dubrot, J. ;

Palazon, A. ;

Hervas-Stubbs, S. ;

Gurpide, A. ;

Lopez-Picazo, J. M. ;

Grande-Pulido, E. ;

Melero, I. ;

Perez-Gracia, J. L. .

BRITISH JOURNAL OF CANCER, 2009, 100 (07) :1111-1119

[2] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[3]

Banchereau J, 2001, CANCER RES, V61, P6451

[4] REGRESSION OF ESTABLISHED TUMORS AND INDUCTION OF TUMOR IMMUNITY BY INTRATUMOR CHEMOTHERAPY [J].

BAST, RC ;

SEGERLING, M ;

OHANIAN, SH ;

GREENE, SL ;

ZBAR, B ;

RAPP, HJ ;

BORSOS, T .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1976, 56 (04) :829-832

[5] Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse [J].

Bates, Gaynor J. ;

Fox, Stephen B. ;

Han, Cheng ;

Leek, Russell D. ;

Garcia, Jose F. ;

Harris, Adrian L. ;

Banham, Alison H. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5373-5380

[6] Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients [J].

Besser, Michal J. ;

Shapira-Frommer, Ronnie ;

Treves, Avraham J. ;

Zippel, Dov ;

Itzhaki, Orit ;

Hershkovitz, Liat ;

Levy, Daphna ;

Kubi, Adva ;

Hovav, Einat ;

Chermoshniuk, Natalia ;

Shalmon, Bruria ;

Hardan, Izhar ;

Catane, Raphael ;

Markel, Gal ;

Apter, Sara ;

Ben-Nun, Alon ;

Kuchuk, Iryna ;

Shimoni, Avichai ;

Nagler, Arnon ;

Schachter, Jacob .

CLINICAL CANCER RESEARCH, 2010, 16 (09) :2646-2655

[7] CROSS-PRIMING FOR A SECONDARY CYTOTOXIC RESPONSE TO MINOR H-ANTIGENS WITH H-2 CONGENIC CELLS WHICH DO NOT CROSS-REACT IN CYTOTOXIC ASSAY [J].

BEVAN, MJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 1976, 143 (05) :1283-1288

[8] Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine [J].

Beyer, M ;

Kochanek, M ;

Darabi, K ;

Popov, A ;

Jensen, M ;

Endl, E ;

Knolle, PA ;

Thomas, RK ;

von Bergwelt-Baildon, M ;

Bebey, S ;

Hallek, M ;

Schultze, JL .

BLOOD, 2005, 106 (06) :2018-2025

[9] CLEARANCE RATES AND SYSTEMIC EFFECTS OF INTRAVENOUSLY ADMINISTERED INTERLEUKIN-2 (IL-2) CONTAINING PREPARATIONS IN HUMAN-SUBJECTS [J].

BINDON, C ;

CZERNIECKI, M ;

RUELL, P ;

EDWARDS, A ;

MCCARTHY, WH ;

HARRIS, R ;

HERSEY, P .

BRITISH JOURNAL OF CANCER, 1983, 47 (01) :123-133

[10] Toll-dependent selection of microbial antigens for presentation by dendritic cells [J].

Blander, JM ;

Medzhitov, R .

NATURE, 2006, 440 (7085) :808-812

← 1 2 3 4 5 6 7 8 9 10 →